Ublituximab + Ibrutinib in Select B-cell Malignancies
Clinical trial NCT02013128 · COMPLETED
Trial details
- NCT number
- NCT02013128
- Sponsor
- TG Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-06
- Primary completion
- 2015-12-01
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.